CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study (Q27852261)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study	scientific article

Statements

scholarly article

1 reference

13 November 2016

CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study (English)

1 reference

13 November 2016

1 reference

based on heuristic

inferred from title

Katsuyuki Kiura

2

object named as

Katsuyuki Kiura

0 references

author name string

Takashi Seto

1

0 references

Makoto Nishio

3

0 references

Kazuhiko Nakagawa

4

0 references

Makoto Maemondo

5

0 references

Akira Inoue

6

0 references

Toyoaki Hida

7

0 references

Nobuyuki Yamamoto

8

0 references

Hiroshige Yoshioka

9

0 references

Masao Harada

10

0 references

Yuichiro Ohe

11

0 references

Naoyuki Nogami

12

0 references

Kengo Takeuchi

13

0 references

Tadashi Shimada

14

0 references

Tomohiro Tanaka

15

0 references

Tomohide Tamura

16

0 references

publication date

June 2013

0 references

Lancet Oncology Commission

0 references

14

0 references

7

0 references

590-8

0 references

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970142-6

7 January 2021

based on heuristic

inferred from DOI database lookup

A mouse model for EML4-ALK-positive lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970142-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970142-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970142-6

7 January 2021

based on heuristic

inferred from DOI database lookup

ROS1 rearrangements define a unique molecular class of lung cancers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970142-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970142-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970142-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970142-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970142-6

7 January 2021

based on heuristic

inferred from DOI database lookup

CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970142-6

7 January 2021

based on heuristic

inferred from DOI database lookup

CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970142-6

7 January 2021

based on heuristic

inferred from DOI database lookup

EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970142-6

7 January 2021

based on heuristic

inferred from DOI database lookup

RET, ROS1 and ALK fusions in lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970142-6

7 January 2021

based on heuristic

inferred from DOI database lookup

KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970142-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Identification of anaplastic lymphoma kinase fusions in renal cancer: large-scale immunohistochemical screening by the intercalated antibody-enhanced polymer method.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970142-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Accelerated titration designs for phase I clinical trials in oncology

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970142-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970142-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970142-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970142-6

7 January 2021

based on heuristic

inferred from DOI database lookup

More on crizotinib.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970142-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(13)70142-6

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q27852261&oldid=1523881063"